Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience

Objective: Panitumumab administered as monotherapy in colorectal cancer (CRC) has shown response and disease stabilization rates of approximately 30%. The current study aimed to evaluate the progression-free survival (PFS) and overall survival (OS) of patients with metastatic colorectal cancer (mCRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Daoud, Mohamed A., Aboelnaga, Engy M., Mohamed, Wael M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850122/
https://www.ncbi.nlm.nih.gov/pubmed/27144068
http://dx.doi.org/10.28092/j.issn.2095-3941.2015.0009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850122/
https://www.ncbi.nlm.nih.gov/pubmed/27144068
http://dx.doi.org/10.28092/j.issn.2095-3941.2015.0009

Ejemplares similares